Indaptus Therapeutics (NASDAQ:INDP) Trading Up 5.7% – Time to Buy?

Indaptus Therapeutics, Inc. (NASDAQ:INDP) shares rose 5.7% on Thursday . The stock traded as high as $4.04 and last traded at $3.9850. 179,677 shares traded hands during trading, a decline of 72% from the average daily volume of 630,641 shares. The stock had previously closed at $3.77.

Analyst Ratings Changes

Several equities analysts recently issued reports on INDP shares. Wall Street Zen raised Indaptus Therapeutics to a “hold” rating in a research report on Saturday, June 27th. Weiss Ratings reissued a “sell (e+)” rating on shares of Indaptus Therapeutics in a report on Friday, July 17th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company has a consensus rating of “Sell”.

Indaptus Therapeutics Trading Up 5.8%

The company’s 50 day simple moving average is $1.88 and its 200-day simple moving average is $2.22. The firm has a market cap of $531.50 million, a P/E ratio of -0.63 and a beta of 1.17.

Indaptus Therapeutics (NASDAQ:INDP) last announced its quarterly earnings results on Thursday, August 13th. The company reported ($0.02) EPS for the quarter, topping analysts’ consensus estimates of ($1.57) by $1.55.

About Indaptus Therapeutics

Indaptus Therapeutics, Inc is a clinical-stage biotechnology company focused on developing novel immunotherapies for cancer and other serious diseases. The company’s approach is designed to activate the body’s innate and adaptive immune systems to generate a broad, potentially durable therapeutic response.

Indaptus’s lead platform, Decoy20, is based on an engineered formulation of inactivated bacteria intended to stimulate immune cells without causing an active infection. The company has been evaluating Decoy20 as a treatment for advanced solid tumors, including in combination with other cancer therapies.